Valuation: Arsanis Inc

Market Cap 390M 341M 313M 292M 553M 37.09B 562M 3.76B 1.46B 18.23B 1.46B 1.43B 62.82B P/E 2026 *
-5.47x
P/E 2027 * -5.02x
Enterprise Value 301M 263M 241M 225M 427M 28.62B 433M 2.9B 1.13B 14.07B 1.13B 1.1B 48.47B EV / Sales 2026 *
31.6x
EV / Sales 2027 * 22.5x
Free-Float
92.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO 71 2025-08-11
President - 2025-08-11
Director TitleAgeSince
Chairman 71 2018-06-30
Director/Board Member 63 2018-09-30
Director/Board Member 65 2019-03-28
Change 5-day change 1-year change 3-year change Capi.($)
+27.91%-3.04% - - 390M
+1.86%+0.48%+55.50%+160.66% 1,082B
+3.57%+3.29%+68.60%+61.56% 633B
+3.99%+3.05%+37.93%+89.70% 461B
-1.32%+1.37%+31.00%+23.05% 338B
-1.43%-0.44%+39.31%+37.83% 299B
-0.39%+0.90%+30.46%+45.25% 291B
-0.87%+2.70%-26.70%-40.23% 222B
+3.55%+4.41%+25.45%+65.64% 202B
+4.21%+2.65%+17.47%+69.95% 163B
Average +2.18%+4.45%+31.00%+57.05% 410.27B
Weighted average by Cap. -0.75%+5.43%+41.76%+81.88%

Financials

2026 *2027 *
Net sales 9.5M 8.3M 7.63M 7.11M 13.49M 905M 13.7M 91.63M 35.62M 445M 35.66M 34.89M 1.53B 9.58M 8.37M 7.69M 7.17M 13.6M 912M 13.81M 92.35M 35.9M 448M 35.94M 35.17M 1.54B
Net income -98.38M -86M -79.03M -73.67M -140M -9.37B -142M -949M -369M -4.6B -369M -361M -15.87B -117M -102M -93.62M -87.26M -166M -11.09B -168M -1.12B -437M -5.45B -437M -428M -18.79B
Net Debt -89M -77.8M -71.5M -66.65M -126M -8.47B -128M -858M -334M -4.17B -334M -327M -14.35B -174M -153M -140M -131M -248M -16.61B -252M -1.68B -654M -8.17B -655M -641M -28.14B
Logo Arsanis Inc
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-